Skip to main content
Erschienen in: Journal of Neurology 5/2019

20.02.2019 | Original Communication

Color perception impairment following optic neuritis and its association with retinal atrophy

verfasst von: Netta Levin, Michael Devereux, Atira Bick, Nick Baker, Ari Green

Erschienen in: Journal of Neurology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Emphasis is often placed on the good recovery of vision following optic neuritis (ON). However, patients continue to perceive difficulties in performing everyday visual tasks and have reduced visual quality of life. This is in addition to documented permanent loss of retinal volume.

Methods

Seventy-five subjects following monocular ON (> 3 months prior to assessment), were evaluated by the Rabin cone contrast test (CCT). Red, green and blue cone contrast scores were extracted for the affected and fellow eyes. Retinal nerve fiber layer (RNFL) and macular volume (MV) were assessed using optical coherence tomography.

Results

Fifty-seven patients had multiple sclerosis and 17 had clinically isolated syndrome. Median time from ON to evaluation was 47 months. Expanded Disability Status Scale (EDSS) ranged between 0 and 6.5 with average of 2 ± 1.3. Cone contrast scores for red, green and blue in the affected eyes were significantly lower than in the fellow eyes. RNFL thickness and MV were reduced in the affected compared to the fellow eyes. Positive correlations between CCT and RNFL were found in both eyes, but much stronger in the affected eyes (r = 0.72, 0.74, 0.5 and 0.53, 0.58, 0.46 for red green and blue in each eye, respectively). Positive correlations between CCT and MV were found in both eyes, but only modestly stronger in the affected eyes.

Conclusions

Impaired chromatic discrimination thresholds quantitatively document persistent functional complaints after ON. There is evidence of dysfunction in both the affected eye and the fellow eye.
Literatur
1.
2.
Zurück zum Zitat Hanson JV et al (2016) Optical coherence tomography in multiple sclerosis. Semin Neurol 36(2):177–184CrossRefPubMed Hanson JV et al (2016) Optical coherence tomography in multiple sclerosis. Semin Neurol 36(2):177–184CrossRefPubMed
3.
Zurück zum Zitat Beck RW et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588CrossRefPubMed Beck RW et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588CrossRefPubMed
5.
Zurück zum Zitat Katz B (1995) The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc 93:685–708PubMedPubMedCentral Katz B (1995) The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc 93:685–708PubMedPubMedCentral
6.
Zurück zum Zitat Schneck ME, Haegerstrom-Portnoy G (1997) Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 38(11):2278–2289PubMed Schneck ME, Haegerstrom-Portnoy G (1997) Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 38(11):2278–2289PubMed
7.
Zurück zum Zitat Cranwell MB et al (2015) Performance on the Farnsworth-Munsell 100-Hue test is significantly related to nonverbal IQ. Invest Ophthalmol Vis Sci 56(5):3171–3178CrossRefPubMed Cranwell MB et al (2015) Performance on the Farnsworth-Munsell 100-Hue test is significantly related to nonverbal IQ. Invest Ophthalmol Vis Sci 56(5):3171–3178CrossRefPubMed
8.
Zurück zum Zitat Lampert EJ et al (2015) Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. J Neurol 262(11):2491–2497CrossRefPubMed Lampert EJ et al (2015) Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. J Neurol 262(11):2491–2497CrossRefPubMed
9.
Zurück zum Zitat Martinez-Lapiscina EH et al (2014) Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler 20(9):1207–1216CrossRefPubMed Martinez-Lapiscina EH et al (2014) Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler 20(9):1207–1216CrossRefPubMed
10.
Zurück zum Zitat Villoslada P et al (2012) Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 18(7):991–999CrossRefPubMed Villoslada P et al (2012) Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 18(7):991–999CrossRefPubMed
11.
Zurück zum Zitat Rabin J, Gooch J, Ivan D (2011) Rapid quantification of color vision: the cone contrast test. Invest Ophthalmol Vis Sci 52(2):816–820CrossRefPubMed Rabin J, Gooch J, Ivan D (2011) Rapid quantification of color vision: the cone contrast test. Invest Ophthalmol Vis Sci 52(2):816–820CrossRefPubMed
12.
Zurück zum Zitat Fujikawa M et al (2018) Evaluation of clinical validity of the Rabin cone contrast test in normal phakic or pseudophakic eyes and severely dichromatic eyes. Acta Ophthalmol 96(2):e164–e167CrossRefPubMed Fujikawa M et al (2018) Evaluation of clinical validity of the Rabin cone contrast test in normal phakic or pseudophakic eyes and severely dichromatic eyes. Acta Ophthalmol 96(2):e164–e167CrossRefPubMed
13.
Zurück zum Zitat Balcer LJ et al (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68(16):1299–1304CrossRefPubMed Balcer LJ et al (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68(16):1299–1304CrossRefPubMed
14.
Zurück zum Zitat Raftopoulos R et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259–269CrossRefPubMed Raftopoulos R et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259–269CrossRefPubMed
15.
Zurück zum Zitat Green AJ et al (2017) Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 390(10111):2481–2489CrossRefPubMed Green AJ et al (2017) Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 390(10111):2481–2489CrossRefPubMed
16.
Zurück zum Zitat Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical trials of new agents in multiple sclerosis. Neurology 46(4):907–911CrossRefPubMed Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical trials of new agents in multiple sclerosis. Neurology 46(4):907–911CrossRefPubMed
17.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed
18.
Zurück zum Zitat Schippling S et al (2015) Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler 21(2):163–170CrossRefPubMed Schippling S et al (2015) Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler 21(2):163–170CrossRefPubMed
19.
Zurück zum Zitat Cruz-Herranz A et al (2016) The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 86(24):2303–2309CrossRefPubMedPubMedCentral Cruz-Herranz A et al (2016) The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 86(24):2303–2309CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Mowry EM et al (2009) Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry 80(7):767–772CrossRefPubMed Mowry EM et al (2009) Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry 80(7):767–772CrossRefPubMed
21.
Zurück zum Zitat Raz N et al (2011) Sustained motion perception deficit following optic neuritis: behavioral and cortical evidence. Neurology 76(24):2103–2111CrossRefPubMed Raz N et al (2011) Sustained motion perception deficit following optic neuritis: behavioral and cortical evidence. Neurology 76(24):2103–2111CrossRefPubMed
22.
Zurück zum Zitat Almog Y, Nemet A (2010) The correlation between visual acuity and color vision as an indicator of the cause of visual loss. Am J Ophthalmol 149(6):1000–1004CrossRefPubMed Almog Y, Nemet A (2010) The correlation between visual acuity and color vision as an indicator of the cause of visual loss. Am J Ophthalmol 149(6):1000–1004CrossRefPubMed
23.
Zurück zum Zitat Porciatti V, Sartucci F (1996) Retinal and cortical evoked responses to chromatic contrast stimuli. Specific losses in both eyes of patients with multiple sclerosis and unilateral optic neuritis. Brain 119(Pt 3):723–740CrossRefPubMed Porciatti V, Sartucci F (1996) Retinal and cortical evoked responses to chromatic contrast stimuli. Specific losses in both eyes of patients with multiple sclerosis and unilateral optic neuritis. Brain 119(Pt 3):723–740CrossRefPubMed
24.
Zurück zum Zitat Evangelou N et al (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124(Pt 9):1813–1820CrossRefPubMed Evangelou N et al (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124(Pt 9):1813–1820CrossRefPubMed
25.
Zurück zum Zitat Toussaint D et al (1983) Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 3(3):211–220PubMed Toussaint D et al (1983) Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 3(3):211–220PubMed
26.
Zurück zum Zitat Green AJ et al (2010) Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 133(Pt 6):1591–1601CrossRefPubMedPubMedCentral Green AJ et al (2010) Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 133(Pt 6):1591–1601CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Oberwahrenbrock T et al (2013) Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler 19(14):1887–1895CrossRefPubMed Oberwahrenbrock T et al (2013) Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler 19(14):1887–1895CrossRefPubMed
28.
Zurück zum Zitat Brandt AU et al (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134(Pt 11):e193 (author reply e194) CrossRefPubMed Brandt AU et al (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134(Pt 11):e193 (author reply e194) CrossRefPubMed
29.
Zurück zum Zitat Balcer LJ et al (2015) Vision and vision-related outcome measures in multiple sclerosis. Brain 138(Pt 1):11–27CrossRefPubMed Balcer LJ et al (2015) Vision and vision-related outcome measures in multiple sclerosis. Brain 138(Pt 1):11–27CrossRefPubMed
Metadaten
Titel
Color perception impairment following optic neuritis and its association with retinal atrophy
verfasst von
Netta Levin
Michael Devereux
Atira Bick
Nick Baker
Ari Green
Publikationsdatum
20.02.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 5/2019
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09246-8

Weitere Artikel der Ausgabe 5/2019

Journal of Neurology 5/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.